Long-term Outcomes of Frontline Intensification in Primary CNS Lymphoma: A Real-world Single-center Experience

Overview

Journal Cancer Med

Specialty Oncology

Date 2023 Jan 17

PMID 36647765

Authors

Hao-Yuan Wang

Ching-Fen Yang

Chia-Hsin Lin

Liang-Tsai Hsiao

Po-Shen Ko

Yao-Chung Liu

Tzeon-Jye Chiou

Po-Min Chen

Jyh-Pyng Gau

Jin-Hwang Liu

Chia-Jen Liu

Affiliations

Soon will be listed here.

Abstract

Background: Frontline intensification (including consolidative whole-brain radiotherapy or high-dose chemotherapy with autologous stem-cell transplantation after induction therapy) has been proposed to treat primary central nervous system lymphoma (PCNSL). However, no prospective randomized trials have answered whether frontline intensification can offer a survival benefit to PCNSL patients. We aim to clarify the outcomes and survival influence of frontline intensification on real-world patients with different risk-stratified PCNSLs.

Methods: Between January 2003 and December 2016, 110 PCNSL adults were retrospectively included, and 76 patients achieved at least PR after induction therapy, including 38 patients who received frontline intensification. The median follow-up with the 31 survivors was 7.52 years.

Results: Of the 38 induction-completed patients who had not received frontline intensification, 95% achieved post-induction therapy CR/CRu; however, all inevitably recurred. In the 38 who received frontline intensification, CR/CRu improved from 45% (pre-frontline intensification) to 84% (post-frontline intensification), and they achieved significantly better PFS (non-reach vs. 522 days, p < 0.001) and OS (non-reach vs. 899 days, p < 0.001). Additionally, patients had similar PFS and OS rates when receiving HDC-ASCT and/or WBRT as frontline intensification. Frontline intensification significantly improved PFS and OS survival in higher-risk patients (intermediate/high IELSG risk, MSKCC group 2/3, or Nottingham/Barcelona score ≥ 2 points) but did not improve OS in lower-risk patients. Among the 38 patients who received frontline intensification, two had treatment-related mortality; 14 recurred after frontline intensification. MTX-based chemotherapy was the main salvage modality, and the median OS was 295 days after recurrence. Progressive disease and infection (especially pneumonia) are two major causes of mortality in patients who receive frontline intensification.

Conclusions: When achieving CR/CRu/PR after induction chemotherapy, frontline intensification should be adopted to improve PFS and OS in real-world PCNSL patients, especially higher-risk patients.

Citing Articles

Long-term outcomes of frontline intensification in primary CNS lymphoma: A real-world single-center experience.

Wang H, Yang C, Lin C, Hsiao L, Ko P, Liu Y Cancer Med. 2023; 12(7):8089-8101.

PMID: 36647765 PMC: 10134300. DOI: 10.1002/cam4.5607.

References

Ferreri A, Cwynarski K, Pulczynski E, Fox C, Schorb E, La Rosee P . Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International.... Lancet Haematol. 2017; 4(11):e510-e523. DOI: 10.1016/S2352-3026(17)30174-6. View

Blay J, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H . High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998; 16(3):864-71. DOI: 10.1200/JCO.1998.16.3.864. View

Abrey L, Batchelor T, Ferreri A, Gospodarowicz M, Pulczynski E, Zucca E . Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005; 23(22):5034-43. DOI: 10.1200/JCO.2005.13.524. View

Zeremski V, Koehler M, Fischer T, Schalk E . Characteristics and outcome of patients with primary CNS lymphoma in a "real-life" setting compared to a clinical trial. Ann Hematol. 2016; 95(5):793-9. DOI: 10.1007/s00277-016-2602-5. View

Ferreri A, Illerhaus G . The role of autologous stem cell transplantation in primary central nervous system lymphoma. Blood. 2016; 127(13):1642-9. DOI: 10.1182/blood-2015-10-636340. View

Bessell E, Graus F, Lopez-Guillermo A, Lewis S, Villa S, Verger E . Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors. Int J Radiat Oncol Biol Phys. 2004; 59(2):501-8. DOI: 10.1016/j.ijrobp.2003.11.001. View

Morris P, Correa D, Yahalom J, Raizer J, Schiff D, Grant B . Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013; 31(31):3971-9. PMC: 5569679. DOI: 10.1200/JCO.2013.50.4910. View

Abrey L, Moskowitz C, Mason W, Crump M, Stewart D, Forsyth P . Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003; 21(22):4151-6. DOI: 10.1200/JCO.2003.05.024. View

Abrey L, Ben-Porat L, Panageas K, Yahalom J, Berkey B, Curran W . Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006; 24(36):5711-5. DOI: 10.1200/JCO.2006.08.2941. View

10.

Omuro A, Correa D, DeAngelis L, Moskowitz C, Matasar M, Kaley T . R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015; 125(9):1403-10. PMC: 4342354. DOI: 10.1182/blood-2014-10-604561. View

11.

Houillier C, Soussain C, Ghesquieres H, Soubeyran P, Chinot O, Taillandier L . Management and outcome of primary CNS lymphoma in the modern era: An LOC network study. Neurology. 2020; 94(10):e1027-e1039. PMC: 7238921. DOI: 10.1212/WNL.0000000000008900. View

12.

Yoon D, Lee D, Choi D, Sohn B, Kim S, Kim S . Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Bone Marrow Transplant. 2010; 46(1):105-9. DOI: 10.1038/bmt.2010.71. View

13.

Ferreri A, Blay J, Reni M, Pasini F, Spina M, Ambrosetti A . Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003; 21(2):266-72. DOI: 10.1200/JCO.2003.09.139. View

14.

Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A . High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006; 38(6):417-20. DOI: 10.1038/sj.bmt.1705452. View

15.

Citterio G, Reni M, Gatta G, Maria Ferreri A . Primary central nervous system lymphoma. Crit Rev Oncol Hematol. 2017; 113:97-110. DOI: 10.1016/j.critrevonc.2017.03.019. View

16.

Houillier C, Taillandier L, Dureau S, Lamy T, Laadhari M, Chinot O . Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019; 37(10):823-833. DOI: 10.1200/JCO.18.00306. View

17.

Illerhaus G, Marks R, Ihorst G, Guttenberger R, Ostertag C, Derigs G . High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol. 2006; 24(24):3865-70. DOI: 10.1200/JCO.2006.06.2117. View

18.

Lauer E, Mutter J, Scherer F . Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research. Leukemia. 2022; 36(9):2151-2164. PMC: 9417989. DOI: 10.1038/s41375-022-01618-w. View

19.

Scordo M, Wang T, Ahn K, Chen Y, Ahmed S, Awan F . Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021; 7(7):993-1003. PMC: 8283558. DOI: 10.1001/jamaoncol.2021.1074. View

20.

Ferreri A, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi L . Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016; 3(5):e217-27. DOI: 10.1016/S2352-3026(16)00036-3. View